PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.50
Current Ratio near Drug Manufacturers - Specialty & Generic median of 2.38. Charlie Munger would see it as typical for the industry.
2.50
Quick Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 1.85. Mohnish Pabrai might see the market underpricing this strong liquidity position.
0.07
Cash Ratio below 0.5x Drug Manufacturers - Specialty & Generic median of 0.64. Jim Chanos might suspect near-term shortfall risks if credit markets seize up.
-86.02
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.